Skip to main content
Top
Published in: Journal of Inflammation 1/2024

Open Access 01-12-2024 | Research

Tissue-plasminogen activator effects on the phenotype of splenic myeloid cells in acute inflammation

Authors: Célia Seillier, Léonie Lesec, Pauline Hélie, Charlotte Marie, Denis Vivien, Fabian Docagne, Brigitte Le Mauff, Olivier Toutirais

Published in: Journal of Inflammation | Issue 1/2024

Login to get access

Abstract

Tissue-plasminogen activator (tPA) is a serine protease well known for its fibrinolytic function. Recent studies indicate that tPA could also modulate inflammation via plasmin generation and/or by receptor mediated signalling in vitro. However, the contribution of tPA in inflammatory processes in vivo has not been fully addressed. Therefore, using tPA-deficient mice, we have analysed the effect of lipopolysaccharide (LPS) challenge on the phenotype of myeloid cells including neutrophils, macrophages and dendritic cells (DCs) in spleen. We found that LPS treatment upregulated the frequency of major histocompatibility class two (MHCII+) macrophages but also, paradoxically, induced a deep downregulation of MHCII molecule level on macrophages and on conventional dendritic cells 2 (cDC2). Expression level of the CD11b integrin, known as a tPA receptor, was upregulated by LPS on MHCII+ macrophages and cDC2, suggesting that tPA effects could be amplified during inflammation. In tPA−/− mice under inflammatory conditions, expression of costimulatory CD86 molecules on MHCII+ macrophages was decreased compared to WT mice, while in steady state the expression of MHCII molecules was higher on macrophages. Finally, we reported that tPA deficiency slightly modified the phenotype of DCs and T cells in acute inflammatory conditions. Overall, our findings indicate that in vivo, LPS injection had an unexpectedly bimodal effect on MHCII expression on macrophages and DCs that consequently might affect adaptive immunity. tPA could also participate in the regulation of the T cell response by modulating the levels of CD86 and MHCII molecules on macrophages.
Appendix
Available only for authorised users
Literature
11.
go back to reference Morelli AE, Larregina AT, Shufesky WJ, Zahorchak AF, Logar AJ, Papworth GD, Wang Z, Watkins SC, Falo LD, Thomson AW. Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production. Blood. 2003;101:611–20. https://doi.org/10.1182/blood-2002-06-1769.CrossRefPubMed Morelli AE, Larregina AT, Shufesky WJ, Zahorchak AF, Logar AJ, Papworth GD, Wang Z, Watkins SC, Falo LD, Thomson AW. Internalization of circulating apoptotic cells by splenic marginal zone dendritic cells: dependence on complement receptors and effect on cytokine production. Blood. 2003;101:611–20. https://​doi.​org/​10.​1182/​blood-2002-06-1769.CrossRefPubMed
20.
go back to reference Lin L, Hu K. Tissue plasminogen activator and inflammation: from phenotype to signaling mechanisms. Am J Clin Exp Immunol. 2014;3:30–6.PubMedPubMedCentral Lin L, Hu K. Tissue plasminogen activator and inflammation: from phenotype to signaling mechanisms. Am J Clin Exp Immunol. 2014;3:30–6.PubMedPubMedCentral
30.
go back to reference Gunner CB, Azmoon P, Mantuano E, Das L, Zampieri C, Pizzo SV, Gonias SL. An antibody that targets cell-surface glucose-regulated protein-78 inhibits expression of inflammatory cytokines and plasminogen activator inhibitors by macrophages. J Cell Biochem. 2023;124:743–52. https://doi.org/10.1002/jcb.30401.CrossRefPubMed Gunner CB, Azmoon P, Mantuano E, Das L, Zampieri C, Pizzo SV, Gonias SL. An antibody that targets cell-surface glucose-regulated protein-78 inhibits expression of inflammatory cytokines and plasminogen activator inhibitors by macrophages. J Cell Biochem. 2023;124:743–52. https://​doi.​org/​10.​1002/​jcb.​30401.CrossRefPubMed
33.
go back to reference R. Renckens, J.J.T.H. Roelofs, S. Florquin, A.F. de Vos, J.M. Pater, H.R. Lijnen, P. Carmeliet, C. van ’t Veer, T. van der Poll, Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice, J Immunol. 177 (2006) 1189–1196. https://doi.org/10.4049/jimmunol.177.2.1189. R. Renckens, J.J.T.H. Roelofs, S. Florquin, A.F. de Vos, J.M. Pater, H.R. Lijnen, P. Carmeliet, C. van ’t Veer, T. van der Poll, Endogenous tissue-type plasminogen activator is protective during Escherichia coli-induced abdominal sepsis in mice, J Immunol. 177 (2006) 1189–1196. https://​doi.​org/​10.​4049/​jimmunol.​177.​2.​1189.
37.
40.
46.
go back to reference Hart PH, Burgess DR, Vitti GF, Hamilton JA. Interleukin-4 stimulates human monocytes to produce tissue-type plasminogen activator. Blood. 1989;74:1222–5.CrossRefPubMed Hart PH, Burgess DR, Vitti GF, Hamilton JA. Interleukin-4 stimulates human monocytes to produce tissue-type plasminogen activator. Blood. 1989;74:1222–5.CrossRefPubMed
47.
go back to reference Steeg PS, Johnson HM, Oppenheim JJ. Regulation of murine macrophage Ia antigen expression by an immune interferon-like lymphokine: inhibitory effect of endotoxin. J Immunol. 1982;129:2402–6.CrossRefPubMed Steeg PS, Johnson HM, Oppenheim JJ. Regulation of murine macrophage Ia antigen expression by an immune interferon-like lymphokine: inhibitory effect of endotoxin. J Immunol. 1982;129:2402–6.CrossRefPubMed
48.
go back to reference Koerner TJ, Hamilton TA, Adams DO. Suppressed expression of surface Ia on macrophages by lipopolysaccharide: evidence for regulation at the level of accumulation of mRNA. J Immunol. 1987;139:239–43.CrossRefPubMed Koerner TJ, Hamilton TA, Adams DO. Suppressed expression of surface Ia on macrophages by lipopolysaccharide: evidence for regulation at the level of accumulation of mRNA. J Immunol. 1987;139:239–43.CrossRefPubMed
50.
go back to reference Raziuddin S, Kibler RF, Morrison DC. Prevention of experimental allergic encephalomyelitis by bacterial lipopolysaccharides: inhibition of cell-mediated immunity. J Immunol. 1981;127:13–6.CrossRefPubMed Raziuddin S, Kibler RF, Morrison DC. Prevention of experimental allergic encephalomyelitis by bacterial lipopolysaccharides: inhibition of cell-mediated immunity. J Immunol. 1981;127:13–6.CrossRefPubMed
51.
go back to reference P. Hélie, C. Camacho-Toledano, L. Lesec, C. Seillier, A.J. Miralles, M.C. Ortega, S. Guérit, H. Lebas, I. Bardou, V. Vila-Del Sol, D. Vivien, B. Le Mauff, D. Clemente, F. Docagne, O. Toutirais, Tissue plasminogen activator worsens experimental autoimmune encephalomyelitis by complementary actions on lymphoid and myeloid cell responses, J Neuroinflammation. 18 (2021) 52. https://doi.org/10.1186/s12974-021-02102-5. P. Hélie, C. Camacho-Toledano, L. Lesec, C. Seillier, A.J. Miralles, M.C. Ortega, S. Guérit, H. Lebas, I. Bardou, V. Vila-Del Sol, D. Vivien, B. Le Mauff, D. Clemente, F. Docagne, O. Toutirais, Tissue plasminogen activator worsens experimental autoimmune encephalomyelitis by complementary actions on lymphoid and myeloid cell responses, J Neuroinflammation. 18 (2021) 52. https://​doi.​org/​10.​1186/​s12974-021-02102-5.
59.
Metadata
Title
Tissue-plasminogen activator effects on the phenotype of splenic myeloid cells in acute inflammation
Authors
Célia Seillier
Léonie Lesec
Pauline Hélie
Charlotte Marie
Denis Vivien
Fabian Docagne
Brigitte Le Mauff
Olivier Toutirais
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Inflammation / Issue 1/2024
Electronic ISSN: 1476-9255
DOI
https://doi.org/10.1186/s12950-024-00375-0

Other articles of this Issue 1/2024

Journal of Inflammation 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.